FINWIRES · TerminalLIVE
FINWIRES

研究快訊:伊利諾州工具公司:利潤率持續上升;第一季獲利超預期

By

-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師總結如下:ITW第四季每股收益為2.66美元,超出市場預期,主要得益於利潤率提升而非營收成長。營收達40.2億美元,年增4.6%,但內生成長依然疲軟,僅0.4%,匯率波動帶來了3.9%的成長。營業利益率提升60個基點至25.4%,其中企業級措施貢獻了120個基點的提升,延續了營運效率提升與內生成長乏力並存的趨勢。 ITW將2026年全年每股收益預期上調0.10美元至11.10美元至11.50美元,中位數計算成長8%。 ITW多元化業務組合的整體表現參差不齊。焊接業務實現了6%的有機成長,測試與測量業務成長了4.6%,而特種產品業務下降了4.7%,食品設備業務下降了2.8%。儘管利潤率走勢令人鼓舞,且公司上調了業績指引,但我們認為有機銷售持續疲軟令人擔憂,因為ITW難以在其廣泛的業務組合中實現全面增長。

Related Articles

Sectors

Sector Update: Financial

Financial stocks were higher late Thursday afternoon, with the NYSE Financial Index rising 1.3% and the State Street Financial Select Sector SPDR ETF (XLF) up 0.5%.The Philadelphia Housing Index climbed 1.6%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) added 1.5%.Bitcoin (BTC-USD) rose 0.9% to $76,409, and the yield for 10-year US Treasuries decreased 2.8 basis points to 4.39%.In corporate news, AvalonBay Communities (AVB) and Equity Residential (EQR) have held discussions over a potential merger, which would be one of the biggest real estate deals ever, Bloomberg reported. AvalonBay shares were down 1.1%, and Equity Residential was fractionally lower.

$AVB$EQR
Australia

Market Chatter: Zuckerberg, Cook Not Exploring Seattle Seahawks Bid

Meta Platforms (META) CEO Mark Zuckerberg and Apple (AAPL) CEO Tim Cook are not pursuing a bid for the National Football League's Seattle Seahawks, Bloomberg reported on Thursday, citing company and industry sources.A Meta spokesperson said Zuckerberg is not making any investment or bid for the team, while a person familiar with Cook's plans denied his involvement, the report said.Meta and Apple did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $616.43, Change: $-52.69, Percent Change: -7.87%

$AAPL$META
Australia

Axsome Therapeutics Says FDA Approves Auvelity for Alzheimer's Disease Agitation

Axsome Therapeutics (AXSM) said Thursday the US Food and Drug Administration approved Auvelity for the treatment of agitation associated with Alzheimer's disease dementia.The approval was supported by two phase 3 clinical trials that showed the drug significantly improved agitation symptoms and resulted in a longer time to relapse compared with placebo.The medication acts on N-methyl-D-aspartate and sigma-1 receptors in the brain and is also approved for adults with major depressive disorder, the company added.Shares of Axsome were up more than 12% in Thursday trading.Price: $206.45, Change: $+22.50, Percent Change: +12.23%

$AXSM